A family of helminth molecules that modulate innate cell responses via molecular mimicry of host antimicrobial peptides.
Robinson. Mark W MW; Donnelly. Sheila S; Hutchinson. Andrew T AT; To. Joyce J; Taylor. Nicole L NL; Norton. Raymond S RS; Perugini. Matthew A MA; Dalton. John P JP
Key Findings
- The helminth protein FhHDM‑1 has a similar amphipathic helix to human LL‑37.
- Both full‑length FhHDM‑1 and its C‑terminal fragment bind directly to LPS, blocking its interaction with immune receptors.
- In mice, these peptides lowered inflammatory mediator release and protected against LPS‑induced inflammation.
Practical Outcomes
- For biohackers, this shows that LL‑37‑like peptides have potential as anti‑inflammatory agents, but they are still experimental and only tested in animals. No ready‑to‑use protocol or dosage exists yet, so any self‑experimentation would be premature and could carry unknown risks.
Summary
Researchers found that a protein secreted by a liver fluke looks a lot like the human antimicrobial peptide LL‑37 and can stick to bacterial toxin LPS, stopping it from triggering inflammation. In mouse tests, both the full protein and a short piece of it reduced inflammatory signals and protected the animals from LPS‑induced damage, suggesting a new way to calm the immune system.
Abstract
Over the last decade a significant number of studies have highlighted the central role of host antimicrobial (or defence) peptides in modulating the response of innate immune cells to pathogen-associated ligands. In humans, the most widely studied antimicrobial peptide is LL-37, a 37-residue peptide containing an amphipathic helix that is released via proteolytic cleavage of the precursor protein CAP18. Owing to its ability to protect against lethal endotoxaemia and clinically-relevant bacterial infections, LL-37 and its derivatives are seen as attractive candidates for anti-sepsis therapies. We have identified a novel family of molecules secreted by parasitic helminths (helminth defence molecules; HDMs) that exhibit similar biochemical and functional characteristics to human defence peptides, particularly CAP18. The HDM secreted by Fasciola hepatica (FhHDM-1) adopts a predominantly α-helical structure in solution. Processing of FhHDM-1 by F. hepatica cathepsin L1 releases a 34-residue C-terminal fragment containing a conserved amphipathic helix. This is analogous to the proteolytic processing of CAP18 to release LL-37, which modulates innate cell activation by classical toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS). We show that full-length recombinant FhHDM-1 and a peptide analogue of the amphipathic C-terminus bind directly to LPS in a concentration-dependent manner, reducing its interaction with both LPS-binding protein (LBP) and the surface of macrophages. Furthermore, FhHDM-1 and the amphipathic C-terminal peptide protect mice against LPS-induced inflammation by significantly reducing the release of inflammatory mediators from macrophages. We propose that HDMs, by mimicking the function of host defence peptides, represent a novel family of innate cell modulators with therapeutic potential in anti-sepsis treatments and prevention of inflammation.
Study Information
pubmed
2011
2011-05-12T00:00:00.000Z
10.1371/journal.ppat.1002042
139
86